You just read:

SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury

News provided by

SanBio, Inc.

Jun 10, 2013, 01:15 ET